{"id":"NCT01889069","sponsor":"Hoffmann-La Roche","briefTitle":"A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL)","officialTitle":"A Single Arm, Multicentre, Phase IIIB Study to Evaluate Safety, Efficacy and Pharmacokinetic (PK) of Subcutaneous (SC) Rituximab Administered During Induction Phase or Maintenance in Previously Untreated Patients With CD20+ Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-07-31","primaryCompletion":"2019-05-28","completion":"2019-05-28","firstPosted":"2013-06-28","resultsPosted":"2020-08-13","lastUpdate":"2020-08-13"},"enrollment":159,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Lymphoma"],"interventions":[{"type":"DRUG","name":"Rituximab","otherNames":["MabThera","Rituxan"]},{"type":"DRUG","name":"Cyclophosphamide","otherNames":[]},{"type":"DRUG","name":"Vincristine","otherNames":[]},{"type":"DRUG","name":"Doxorubicin","otherNames":[]},{"type":"DRUG","name":"Prednisone","otherNames":[]},{"type":"DRUG","name":"Bendamustine","otherNames":[]}],"arms":[{"label":"Rituximab","type":"EXPERIMENTAL"}],"summary":"This single arm, multicenter study will evaluate the safety, efficacy and pharmacokinetic (PK) of subcutaneous (SC) rituximab in previously untreated participants with cluster of differentiation 20 positive (CD20+) DLBCL or FL. In addition to standard chemotherapy, participants will receive at least 4 doses of rituximab 1400 mg SC once a month during the Induction period, and at least 6 doses of rituximab 1400 mg SC once every two months during the Maintenance period.","primaryOutcome":{"measure":"Percentage of Participants With Administration-Associated Reactions (AAR)","timeFrame":"Baseline up to 54 months","effectByArm":[{"arm":"Diffuse Large B-Cell Lymphoma (DLBCL)","deltaMin":4.2,"sd":null},{"arm":"Follicular Lymphoma (FL)","deltaMin":8.1,"sd":null},{"arm":"Subcutaneous (SC) Rituximab","deltaMin":6.3,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":10},"locations":{"siteCount":39,"countries":["Italy"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":26,"n":72},"commonTop":["Neutropenia","Pyrexia","Cough","Anaemia","Asthenia"]}}